The achievement from the Joyce lab is also likely to yield a powerful tool for evolving new and useful molecules.
The drug candidate RPC1063, which was initially developed at TSRI, has shown potential to significantly improve treatment options for ulcerative colitis patients.
The findings from the Subramaniam lab offer a novel target for drug development to counter a devastating progressive neurological condition.